Search
Powered By HealthLine
Special Offers
Health Tools
 Arthritis Questions and Answers
 Arthritis Symptom Checker
 Arthritis Drug Information
 Preventing Arthritis
 Arthritis Treatment
Featured Conditions
 Osteoarthritis
 Chronic Pain
 Rheumatoid Arthritis
 Diet & Exercise
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Ditropan XL

[Oxybutynin]

Study 1 was a forced dose escalation design, whereas the other studies used a dose adjustment design in which each patient's final dose was adjusted to a balance between improvement of incontinence symptoms and tolerability of side effects. Controlled studies included patients known to be responsive to oxybutynin or other anticholinergic medications, and these patients were maintained on a final dose for up to 2 weeks.

The efficacy results for the three controlled trials are presented in the following tables and figures.
Number of Urge Urinary Incontinence Episodes Per Week

* The difference between DITROPAN XL ® and placebo was statistically significant. * Covariate adjusted mean with missing observations set to baseline values

Text Continues Below



Number of Urge Urinary Incontinence Episodes Per Week (continued)
* Covariate adjusted mean with missing observations set to baseline values

0.0
0.5
1.0
1.5
2.0

0 5 10 15 20 25
Time (hours)

Mean
R-Oxybutynin

Plasma

Concentration
(ngml)

Parameters (units) R-Oxybutynin S-Oxybutynin
C max (ng/ mL) 1.0 (0.6) 1.8 (1.0)
T max (h) 12.7 (5.4) 11.8 (5.3)
t 1/ 2 (h) 13.2 (6.2) 12.4 (6.1)
AUC (0-48) (ng° h/ mL) 18.4 (10.3) 34.2 (16.9)
AUC inf (ng° h/ mL) 21.3 (12.2) 39.5 (21.2)

R-Oxybutynin S-Oxybutynin R-Desethyloxybutynin S-Desethyloxybutynin
Cmax (ng/ mL) 0.7 ± 0.4 1.3 ± 0. 8 7.8 ± 3. 7 4.2 ± 2. 3
Tmax (hr) 5.0 5.0 5. 0 5.0
AUC (ng. hr/ mL) 12.8 ± 7. 0 23.7 ± 14.4 125.1 ± 66.7 73.6 ± 47.7

Study 1 n DITROPAN XL ® n Placebo
Mean Baseline 34 15.9 16 20.9
Mean (SD) Change from Baseline* 34 -15.8 (8.9) 16 -7.6 (8.6)
95% Confidence Interval for Difference (-13.6, -2.8)*
(DITROPAN XL ® -Placebo)

Study 2 n DITROPAN XL ® n oxybutynin
Mean Baseline 53 27.6 52 23.0
Mean (SD) Change from Baseline* 53 -17.6 (11.9) 52 -19.4 (11.9)
95% Confidence Interval for Difference (-2.8, 6.5)
(DITROPAN XL ® -oxybutynin)

** The difference between DITROPAN XL ® and oxybutynin fulfilled the criteria for comparable efficacy. * Covariate adjusted mean with missing observations set to baseline value

Page:  << Prev | 1 | 2 | 3 | 4








About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy